In conclusion, our findings suggest the potential of combining olaparib and IFNα as a promising therapeutic strategy in MPN patients by exploiting the synthetic lethality between germline BRCA1 mutations and the JAK2V617F MPN driver mutation. This evidence concerns the gene BRCA1 and myeloproliferative disorder.